15
Jul

A new crop of biotech IPO hopefuls has filed to reap a combined $175 million, looking to bankroll efforts in oncology, pain and rare diseases with offerings on an up-and-down market.

…read more

Source: Three more biotechs target $175M in IPO cash amid market tumult

    

0 No comments